The purpose of the study is to assess the safety and tolerability of the study drug treatment regimens. Participants will receive one of the injections on a regular schedule and will be followed for several months, during which they will attend clinic visits to report any side effects and to undergo routine examinations, including an endoscopic assessment, which uses a small camera to view the inside of the colon and determine whether the disease has improved. The study tracks any new health problems that arise and looks for signs of improvement in the colon lining.

The purpose of the study is to see whether the combination works better at improving the lining of the gut after 12 weeks. Participants will receive the assigned medication(s) for about three months and will have routine visits where doctors will check symptoms and perform an endoscopic exam, which means a small camera is used to look at the inside of the intestine to see any healing.

The study is organized as a randomized, controlled trial, meaning participants are assigned by chance to one of the two treatment groups and the outcomes are compared. Safety checks and regular follow‑up appointments are part of the schedule to monitor how participants feel during the study period.

People in the study are placed into one of the treatment approaches and then followed over time for about 24 months. During this period, regular check-ups are used to watch for signs that Ulcerative Colitis may be becoming active again, and to monitor safety, side effects, hospital stays, surgery to remove the colon, and death. The study also looks at how well the treatment is taken as prescribed.

Ulcerative Colitis is a long-lasting disease that causes swelling and sores in the large bowel, also called the colon. When the disease becomes active again after a quiet period, this is called a relapse or recurrence. Thiopurines are medicines that lower immune system activity to help control the disease, while mesalazine helps reduce swelling in the bowel.

During the study, the effectiveness of tulisokibart will be monitored over a period of time. The investigation looks at how many people reach clinical remission, a state where the symptoms of the disease are significantly reduced or absent. Researchers will also observe endoscopic improvement, which refers to visible healing of the intestinal lining during a procedure where a camera is used to look inside the body, and histologic-endoscopic mucosal improvement, which means the tissue appears healthy both under a microscope and during a visual examination.

During the study, researchers will monitor how the body handles the medication and how well it works to reduce symptoms. The process involves regular check-ups to track changes in physical health, laboratory results, and signs of healing in the intestinal lining. The study will observe participants over a period of time to see if they reach clinical remission, which is a state where symptoms like blood in the stool and frequent bowel movements are significantly reduced or gone.

The purpose of the study is to determine how safe Vedolizumab is when used over a long period in children who have these conditions. Participants in the study will receive regular infusions of Vedolizumab and will be monitored by healthcare professionals to check for any side effects or changes in their health. The study will also look at how the medication affects the growth and development of the children, as well as their overall well-being.

Throughout the study, researchers will collect information on any health events that occur while the children are receiving the treatment. This will help to understand the safety profile of Vedolizumab in young patients with Ulcerative Colitis or Crohn’s Disease. The study aims to provide valuable insights into the long-term use of this medication in managing these chronic conditions in children.

The purpose of the study is to evaluate how effective and safe guselkumab is for people with moderately to severely active ulcerative colitis. Participants in the study will receive either the medication or a placebo. The study will last for a period of time, during which participants will receive regular injections and attend follow-up visits to monitor their health and the effects of the treatment.

Throughout the study, researchers will assess whether participants achieve clinical remission, which means a significant reduction or disappearance of symptoms. The study aims to provide valuable information about the potential benefits of guselkumab for individuals living with ulcerative colitis.

Participants in the study will receive mirikizumab through a subcutaneous injection, which is a method of delivering medication into the fatty layer of tissue just under the skin. During the course of the study, levels of the drug will be measured in breast milk to understand how much of the substance is present.

The study is divided into different parts. People who join this particular part of the study will be those who have already shown improvement after earlier treatment and have completed certain examinations. The study will look at whether Duvakitug can help keep the condition in a state where symptoms are minimal or absent, which is called remission. During the study, doctors will check the condition of the intestine using an examination that looks inside the bowel, and they will also assess symptoms such as bowel movements, bleeding, and abdominal pain. The study will also look at whether people can stop using steroid medications while maintaining good control of their condition.

Throughout the study, participants will be monitored for any side effects or unwanted reactions to the treatment. The study will measure various aspects of the disease and how it affects daily life, including fatigue levels, quality of life, and the need for hospital care related to ulcerative colitis. Blood samples will be taken to measure the amount of Duvakitug in the body and to check if the body develops any immune response to the medication. The study will also include a longer extension period for people who complete the main part of the study, allowing for continued observation of the medication’s effects and safety over time.

The purpose of this study is to assess how well Duvakitug works as an initial treatment for moderately to severely active Ulcerative Colitis compared to placebo. The study will look at whether the medication can help reduce symptoms and inflammation in the intestines. This is called an induction study, which means it focuses on the first phase of treatment to see if the medication can bring the disease under control.

The study will measure several outcomes to determine if the treatment is working. The main outcome will be the proportion of participants who achieve clinical remission, which means their symptoms have improved significantly or disappeared. Other outcomes include improvements in the appearance of the intestine lining as seen during examination, reduction in symptoms like bowel urgency and abdominal pain, improvements in quality of life, and whether participants need to be hospitalized due to their condition. The study will also monitor any side effects and measure the levels of the medication in the blood over time. The treatment period will last up to 24 weeks.

The study evaluates two treatment options. The first treatment uses mirikizumab, a new type of medicine that is given either as an injection under the skin or through an intravenous infusion. The second treatment approach uses a combination of azathioprine (a medication that reduces immune system activity) and glucocorticoids (anti-inflammatory medications taken by mouth). The purpose is to determine if mirikizumab is more effective than the standard treatment with azathioprine and glucocorticoids in controlling the disease.

The treatment period lasts for 52 weeks (one year). During this time, patients will receive either mirikizumab or the combination of azathioprine and glucocorticoids, depending on which treatment group they are assigned to. Throughout the study, doctors will monitor how well the treatments are working and how they affect the patients’ condition.

The study aims to evaluate how safe and effective tulisokibart is when used over an extended period. The medication is given as a subcutaneous injection using a pre-filled injector device that delivers the medicine under the skin. Some participants will receive tulisokibart, while others will receive placebo through the same type of injection device.

The study will last for approximately 364 days (one year), during which participants will receive regular treatments and undergo various medical assessments. This extension study is specifically designed for people who have previously participated in earlier studies of tulisokibart and have shown benefit from the treatment. Throughout the study, doctors will monitor participants’ health and how well their digestive condition responds to the continued treatment.

The treatments involve different methods of delivery. Some medicines, such as infliximab, ustekinumab, and vedolizumab, are given through intravenous infusion, which is a process where medicine is delivered directly into a vein. Another medicine, filgotinib, is taken as an oral tablet. These medications belong to different classes, including anti-TNF agents, anti-IL12/23, JAK inhibitors, and anti-integrins, which are specific ways that drugs work to target the parts of the immune system causing inflammation.

During the study, participants will receive one of these treatments to see how well it helps maintain health and manage the disease over time. The process involves regular monitoring to check for the disappearance of symptoms like rectal bleeding and changes in bowel habits. The study will observe how these different medicines perform in helping patients achieve long-term stability without the need for steroids, which are a type of medicine often used to reduce swelling and inflammation.

The study examines how patients respond to the treatment by looking at changes in their commensal microbiota, which refers to the helpful bacteria that naturally live inside the gut. Participants will undergo a process to compare their health status and the composition of their intestinal bacteria before starting the vancomycin treatment and after completing it to see if the medicine helps achieve remission, a state where the disease symptoms are gone and the gut is no longer inflamed.

During the study, participants will be assigned to different groups to receive either the combination of LY4268989 and mirikizumab or mirikizumab alone. The process is double-blind, meaning neither the participants nor the researchers know which specific treatment is being administered. The course of the study involves monitoring the participants over a 12-week period to observe how they respond to the medications.

The study consists of an initial phase to see how well the treatment works to control symptoms, followed by an extension period to continue monitoring the effects. During the study, medical professionals will monitor the levels of vixarelimab in the blood and check for anti-drug antibodies, which are substances the body might create in response to a medication. The course of the study involves regular assessments to observe changes in symptoms and the condition of the intestinal lining.

The research focuses on how different doses of the medication affect people over an extended period. During the course of the study, the way the body reacts to the treatment and any potential side effects will be monitored to ensure safety and how well the body tolerates the drug.

The purpose of the study is to evaluate the use of 68Ga-FAPI-46 to detect scar tissue inside the body. This substance is a radiopharmaceutical, which is a specialized drug used for medical imaging. Participants will undergo a PET/CT scan, a method that combines two types of imaging to create detailed pictures of the body’s internal structures. During the process, the substance is administered through an intravenous injection, meaning it is delivered directly into a vein.

Throughout the study, the imaging results will be compared with biological samples to see how well the scan identifies certain markers of scarring. Researchers will also look at how the substance moves through the body and how it can be used to better understand the progression of these diseases. This information may help in finding new ways to diagnose or treat scarring in the future.

The purpose of the study is to see if etrasimod can help children reach clinical remission, a state where the symptoms of the disease are significantly reduced or disappear. During the study, participants will receive the medication in the form of tablets or granules taken by mouth. Over a period of 52 weeks, the way the body processes the medicine and any side effects will be monitored. Medical professionals will also check for changes in growth and physical development to ensure the treatment is safe for younger patients.

The purpose of this study is to evaluate how well XmAb942 works in helping people with moderately to severely active Ulcerative Colitis achieve clinical remission, which means bringing the disease under control so that symptoms improve significantly. The study is divided into two parts. The first part tests the medication in healthy volunteers to check its safety. The second part involves people who have moderate to severe Ulcerative Colitis and have not responded well to previous treatments, lost response to them, or could not tolerate them. Participants in the second part must have had Ulcerative Colitis for at least three months and show active disease with inflammation visible during examination of the bowel.

During the study, participants will be randomly assigned to receive either XmAb942 or placebo. The treatment period lasts up to 48 weeks, with an important assessment at week 12 to see if the medication is working. Doctors will measure improvement by looking at various signs of the disease, including bleeding, bowel movement frequency, and inflammation seen during bowel examination. The study will also monitor any side effects or unwanted reactions that occur during treatment to ensure the safety of participants.

The purpose of this study is to measure how much of the medicine gets into the bloodstream when the capsule is opened and sprinkled on applesauce, strawberry jam, or yoghurt compared to swallowing the capsule whole without food, and also to see how eating food affects the amount of medicine that gets into the bloodstream when the capsule is swallowed whole. This information is important for understanding different ways the medicine can be taken, especially for people who may have difficulty swallowing capsules. The study will involve healthy adult participants who will receive a 30 mg dose of the medicine in different ways during the study.

Participants will take part in a study where they will receive the medicine in different forms on different occasions, allowing researchers to compare how the body processes the medicine under various conditions. Blood samples will be collected to measure the amount of medicine in the bloodstream over time. The study will monitor participants for any unwanted effects that may occur during the treatment period.

The study is divided into two parts, called Part A and Part B. In Part A, researchers will look at changes in the tissue of the intestine after 12 weeks of treatment to see if the disease activity has decreased. In Part B, researchers will check if the treatment can help people achieve clinical remission, which means having no or minimal symptoms of the disease, after 12 weeks of treatment. Participants will receive their assigned treatment and have regular check-ups where doctors will examine their condition. This includes procedures where a flexible tube with a camera is used to look inside the intestine, called endoscopy, and taking small tissue samples to examine under a microscope. Some participants may also be taking corticosteroids, which are medications that reduce inflammation, and they may need to continue or gradually reduce these medications during the study.

Throughout the study, doctors will monitor how the medications are working by checking various signs of the disease. They will measure things like changes in disease scores, improvement in the appearance of the intestine lining, and reduction in symptoms. The study will also track the levels of the study medications in the blood and check if the body develops any immune response to these treatments. Part A will last for 12 weeks, while Part B will continue for up to 48 weeks. The study is expected to start enrolling participants in late 2025 and is planned to be completed by early 2028.

The study is divided into different parts for adults and adolescents. For adults, there is an induction phase and a maintenance phase. During the induction phase, the study will look at whether icotrokinra can help bring the disease under control compared to placebo. This part lasts 12 weeks. If participants respond well to the treatment during induction, they may continue into the maintenance phase, which lasts 40 weeks. During this time, the study will check if icotrokinra can keep the disease under control. For adolescents aged 12 to 17 years, the study focuses on the maintenance phase to see if icotrokinra can keep their condition under control after they have responded to the treatment.

Participants in this study will need to have been diagnosed with Ulcerative Colitis at least 12 weeks before joining. The study will involve regular assessments to measure how active the disease is and how well the treatment is working. The medication is given as a film-coated tablet taken by mouth. The study is expected to run for several years to gather information about the long-term effects of this treatment.

The main goal of this research is to determine if MT-501 is safe and effective for people with moderate to severe forms of these digestive conditions. The study is designed as a Phase 2 platform study, which means it will evaluate multiple treatment approaches for inflammatory bowel disease.

During the study, participants will go through an induction phase where they will take the study medication. Throughout this period, doctors will monitor how well the treatment works by examining the inside of the digestive tract and tracking symptoms. They will also check how the body processes the medication and look for any side effects that may occur. The study will collect information about improvements in the condition of the digestive tract lining and overall disease symptoms.

During the study, participants will receive either SAR442970 or placebo for 16 weeks, followed by a longer treatment period of up to 52 weeks. The medication is administered through injections under the skin, with doses up to 300 milligrams. Patients’ response to treatment will be monitored through various examinations of the intestine and assessment of disease symptoms.

The study will look at how well the treatment works by measuring improvements in intestinal inflammation, bowel movements, and overall disease activity. The research will also track any side effects that may occur during the treatment period. Throughout the study, researchers will monitor the levels of the medication in patients’ blood and check for the development of antibodies against the treatment.

The medication will be given in two different ways: as an intravenous infusion (through a vein) and as a subcutaneous injection (under the skin) using a pre-filled syringe. Some participants will receive the actual medication while others will receive a placebo. The study consists of three main parts: an initial open-label treatment period where all participants receive the medication, followed by a period where participants are randomly assigned to either continue the medication or receive placebo, and finally a long-term extension period.

The purpose of this study is to understand how the medication moves through the body, how well it works, and how safe it is for young patients with ulcerative colitis. The study will measure various aspects of the disease improvement, including the healing of the intestinal lining and the reduction of symptoms such as stomach pain and frequent bowel movements. The total duration of treatment may continue for up to 248 weeks.

The medication will be administered as a solution for injection containing 108 mg of vedolizumab. During the study, participants will receive regular injections of the medication for up to 24 months. The study will monitor how well children and teenagers tolerate long-term treatment with vedolizumab and track any side effects that may occur.

Throughout the study, doctors will watch for any health-related events and track the effectiveness of the treatment. They will pay special attention to how the medication affects the participants’ daily lives and overall well-being. The study includes regular check-ups to monitor the participants’ health and assess how well the digestive conditions are being controlled by the treatment.

The study involves patients taking either efavaleukin alfa or placebo while continuing their current medications such as 5-aminosalicylates, corticosteroids, budesonide, beclomethasone dipropionate, or other immune system medications like azathioprine, 6-mercaptopurine, or methotrexate. The main purpose is to evaluate if efavaleukin alfa can help patients achieve clinical remission after 12 weeks of treatment.

During the study, doctors will monitor how well the treatment works by examining the digestive tract and checking for improvements in symptoms. They will also keep track of any side effects that may occur. The study is designed as a double-blind study, which means neither the patients nor the doctors know who is receiving the actual medication or the placebo during the treatment period.

The study aims to understand the long-term safety and effectiveness of efavaleukin alfa in treating people who have moderate to severe Ulcerative Colitis. This research is a continuation of a previous study, allowing researchers to gather information about how well the medication works and how safe it is when used for an extended period.

During this long-term extension study, participants will continue receiving efavaleukin alfa treatment for up to two years. Throughout this time, doctors will monitor various aspects of the participants’ health, including how well their digestive system is healing and whether their symptoms are improving. They will also keep track of any side effects that may occur during the treatment period.

The purpose of this study is to determine if RO7837195 is effective in inducing remission in people with moderately to severely active Ulcerative Colitis when compared to placebo. The study is designed as a double-blind trial, meaning neither the participants nor the doctors know who receives which treatment during the study. The medication will be tested over a 12-week period, followed by an additional treatment phase.

During the study, participants will receive either RO7837195 or placebo through injections under the skin. The study will monitor various aspects of the disease activity, including symptoms such as stool frequency and bleeding. The researchers will also track how the body processes the medication and check for any potential side effects throughout the study period.

The treatment involves collecting the patient’s own immune cells, specifically T-cells that help regulate the immune system. These cells are processed in a laboratory to increase their numbers and then given back to the patient through an intravenous infusion. The treatment, known as Treg therapy, will be administered over a period of two months.

The purpose of this study is to determine if this cell therapy can help achieve remission in people with ulcerative colitis, meaning a reduction in symptoms such as bleeding and frequent bowel movements. The study will monitor patients for 12 weeks after receiving the treatment to evaluate its effectiveness. Each patient may receive up to two infusions of the processed immune cells during the study period.

The purpose of this study is to determine whether risankizumab is as effective as or more effective than vedolizumab for treating ulcerative colitis over a 48-week period. Participants in this study will have already tried other conventional treatments such as aminosalicylates (anti-inflammatory drugs), steroids, or immunomodulators without adequate relief of their symptoms.

During the study, participants will be randomly assigned to receive either risankizumab or vedolizumab. The study will monitor improvements in the intestinal lining through endoscopy (a procedure where a small camera is used to examine the inside of the colon) and track symptom improvement including stool frequency and rectal bleeding. This is an open-label study, meaning both the healthcare providers and participants will know which medication is being administered.

Participants in the study will first receive the OD-07656 capsule, which is a chemical compound, for a period of up to 12 weeks. After this initial phase, they will receive Vedolizumab, a protein-based medication, for up to 38 weeks. The study will monitor how well these treatments work in reducing the symptoms of Ulcerative Colitis and will also check for any side effects or changes in health indicators like blood tests and heart function.

The trial aims to provide valuable information on whether these treatments can help manage the symptoms of Ulcerative Colitis and improve the quality of life for those affected by this condition. Participants will be closely monitored throughout the study to ensure their safety and to gather data on the effectiveness of the treatments.

The purpose of the study is to evaluate a new treatment approach for patients with Ulcerative Colitis who are identified as having a potentially severe outcome within one year. This approach, known as a “top-down” strategy, involves starting treatment with biologic therapy early on, rather than following the usual step-by-step method. The study aims to determine if this early intervention can lead to a higher chance of achieving deep remission, which means the disease is not active, one year after the initial diagnosis.

Participants in the study will receive the treatment and be monitored over time to assess their response. The study will look at various outcomes, including the percentage of patients who achieve deep remission after one year and those who start with biological medication or require surgery within the first year. Additionally, the study will evaluate patient-reported outcomes related to quality of life and medical expenses. The trial is expected to continue until the end of 2031, with recruitment starting in 2025.

The main purpose of the study is to understand the amount of Etrasimod Arginine that is secreted into breast milk after taking the medicine regularly. Participants in the study will be healthy women who are breastfeeding and are at least 12 weeks postpartum. They will be required to temporarily stop breastfeeding their infants for a period of 21 days while they take the medication and continue to express breast milk to maintain lactation.

Throughout the study, the participants will take the medicine orally and their blood and breast milk will be tested to measure how much of the medicine is present. This will help researchers learn more about the safety and behavior of Etrasimod Arginine in the body, particularly in breastfeeding women. The study aims to provide valuable information that could contribute to the development of treatments for Ulcerative Colitis and similar conditions.

The purpose of the study is to compare the effectiveness of the fecal microbiota transplant to the placebo in achieving remission of ulcerative colitis without the use of steroids. Participants in the study will receive either the fecal microbiota transplant or the placebo through a rectal procedure. The study will monitor the participants over a period of 12 weeks to assess their response to the treatment.

Throughout the study, researchers will evaluate the participants’ health by looking at various factors, including the healing of the colon lining and changes in the gut bacteria. The study aims to determine if the fecal microbiota transplant can help patients maintain remission from ulcerative colitis without relying on steroids, which are commonly used to manage the condition. Participants will be closely monitored for any side effects or changes in their condition during the study period.

The purpose of the study is to learn more about how the body absorbs the Etrasimod Arginine mini tablets when they are mixed with different foods like applesauce, chocolate pudding, yogurt, or just water. The study will also look at how the mini tablets taste when mixed with these foods. Participants in the study will take a single dose of the mini tablets in different forms, and researchers will compare how the body absorbs the medication in each case.

The study involves healthy adult participants who will take part in a series of tests to see how the medication is absorbed and how it tastes. The study will help researchers understand the best way to deliver the medication to patients in the future. Participants will be monitored for any side effects and will provide feedback on the taste and feel of the mini tablets. This information will be used to improve the medication for future use in treating the diseases being studied.

The purpose of the study is to evaluate how tofacitinib affects platelet function and blood clotting in patients with ulcerative colitis. Participants will receive one of the medications, and their platelet activity will be monitored before and after starting the treatment. The study will last for up to 12 months, during which time the effects of the medication on the participants’ condition will be observed and recorded.

Throughout the study, the activity of the disease will be assessed using a method called the Mayo endoscopic sub-score, which helps determine the severity of the inflammation in the colon. The study aims to understand better how these medications can help manage ulcerative colitis and improve patient outcomes by reducing inflammation and preventing complications related to blood clotting.

Participants in the study will receive different doses of SAR441566 or a placebo to compare the outcomes. The study will monitor participants over a period of time to see if the treatment helps them achieve clinical remission, which means a significant reduction or disappearance of symptoms. The study will also look at other outcomes, such as improvements in symptoms reported by patients and changes observed during medical examinations.

The trial will last for several weeks, and participants will have regular check-ups to assess their progress. The study aims to gather information on how well SAR441566 works and its safety profile, which includes monitoring any side effects that may occur during the treatment period. This information will help determine if SAR441566 could be a beneficial treatment option for people with ulcerative colitis in the future.

The purpose of the study is to evaluate how well participants tolerate the medication over an extended period. Participants who have already shown a response to the treatment in previous trials will continue to take zasocitinib in capsule form. The study will last for up to 108 weeks, during which time participants will be monitored for any side effects or changes in their health. Some participants will receive a placebo, which is a substance with no active medication, to compare the effects of the actual drug.

Throughout the study, participants will have regular check-ups to assess their health, including monitoring vital signs and conducting laboratory tests. The study aims to gather information on the long-term effects of zasocitinib to better understand its safety and effectiveness in treating Ulcerative Colitis and Crohn’s Disease.